The FDA on April 22, 2021 granted accelerated approval to JEMPERLIĀ® for adult patients with MisMatch Repair deficient (dMMR) recurrent or advanced Endometrial cancer, as determined by an FDA-approved test, that has progressed on or following a prior Platinum-containing regimen. JEMPERLIĀ® is a product of GlaxoSmithKline LLC.
Other Pages – Bottom Ad
Advertisement
Subscribe
